WallStreetZenWallStreetZen

NYSE: ABT
ABBOTT LABORATORIES Earnings & Revenue

Buy ABT
OverviewForecastEarnings
DividendOwnership

ABT past earnings growth

How has ABT's earnings growth performed historically?
Company
35.94%
Industry
60.04%
Market
75.85%
ABT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ABT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ABT's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ABT past revenue growth

How has ABT's revenue growth performed historically?
Company
19.22%
Industry
21.3%
Market
54.3%
ABT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ABT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ABT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ABT earnings and revenue history

Current Revenue
$44.5B
Current Earnings
$7.7B
Current Profit Margin
17.4%
ABT's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

ABT Return on Equity

Current Company
22%
Current Industry
11.5%
Current Market
38.4%
ABT's Return on Equity (22%)... subscribe to Premium to read more.
High Return on Equity Performance

ABT Return on Assets

Current Company
10.4%
Current Industry
6.1%
ABT is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ABT Return on Capital Employed

Current Company
15.6%
Current Industry
9.1%
ABT has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ABT vs Medical Device Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ABT$44.51B$13.00B$7.73B+14.82%+35.28%
MDT$31.69B$8.76B$5.04B+1.30%+5.13%
SYK$17.43B$2.67B$2.02B+8.14%+3.43%
EW$5.36B$1.93B$1.54B+11.21%+19.21%
BSX$12.16B$2.54B$754.00M+7.22%+9.52%
View Top Medical Device Stocks

ABT earnings dates

Next earnings date
Jul 20, 2022

ABBOTT LABORATORIES Earnings & Revenue FAQ

What were ABT's earnings last quarter?

On Invalid Date, ABBOTT LABORATORIES (NYSE: ABT) reported Q1 2022 earnings per share (EPS) of $1.38, up 38% year over year. Total ABBOTT LABORATORIES earnings for the quarter were $2.45 billion. In the same quarter last year, ABBOTT LABORATORIES's earnings per share (EPS) was $1.00.

What was ABT's earnings growth in the past year?

As of Q2 2022, ABBOTT LABORATORIES's earnings has grown 35.94% year over year. This is 24.1 percentage points lower than the US Medical Devices industry earnings growth rate of 60.04%. ABBOTT LABORATORIES's earnings in the past year totalled $7.73 billion.

What is ABT's earnings date?

ABBOTT LABORATORIES's earnings date is Invalid Date. Add ABT to your watchlist to be reminded of ABT's next earnings announcement.

What was ABT's revenue last quarter?

On Invalid Date, ABBOTT LABORATORIES (NYSE: ABT) reported Q1 2022 revenue of $11.90 billion up 13.76% year over year. In the same quarter last year, ABBOTT LABORATORIES's revenue was $10.46 billion.

What was ABT's revenue growth in the past year?

As of Q2 2022, ABBOTT LABORATORIES's revenue has grown 19.22% year over year. This is 2.08 percentage points lower than the US Medical Devices industry revenue growth rate of 21.3%. ABBOTT LABORATORIES's revenue in the past year totalled $44.51 billion.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending StocksStock Market SectorsStock Market Industries
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.